Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr….
A Shift to Non-Combustible Tobacco Devices Results in a Smoking Rate Decline by an Average of 5.2%: Says Expert
World Heart Day 2023 approaches, aligning with this year’s theme, ‘Striving for Hearts that Beat Strong.’ It serves as a touching reminder to prioritize our heart health. Recently, distinguished Indian and international health experts convened at the prestigious AIIMS, New…
Venus Remedies on expansion spree in Gulf, gets Saudi marketing approval for Enoxaparin in PFS
Making rapid global strides by expanding its reach in the Gulf, Venus Remedies Ltd, a leading exporter of affordable generic drugs with presence in more than 80 countries, has received marketing approval from Saudi Arabia, the largest pharmaceutical market in…
